Digitalis Toxicity

Digitalis Toxicity: A Fading but Crucial Complication to Recognize

The American Journal of Medicine ◽

10.1016/j.amjmed.2011.09.019 ◽

2012 ◽

Vol 125 (4) ◽

pp. 337-343 ◽

Cited By ~ 31

Author(s):

Eric H. Yang ◽

Sonia Shah ◽

John M. Criley

Keyword(s):

Digitalis Toxicity

Download Full-text

drug interactions and digitalis toxicity

AJN American Journal of Nursing ◽

10.1097/00000446-198080120-00020 ◽

1980 ◽

Vol 80 (12) ◽

pp. 2170-2171

Author(s):

Anne L. Cavanaugh ◽

Robert E. Mancini

Keyword(s):

Drug Interactions ◽

Digitalis Toxicity

Download Full-text

Digitalis Toxicity and Serum Levels

New England Journal of Medicine ◽

10.1056/nejm197112302852722 ◽

1971 ◽

Vol 285 (27) ◽

pp. 1540-1541

Keyword(s):

Serum Levels ◽

Digitalis Toxicity

Download Full-text

Fab Fragments in Treatment of Digoxin Ingestion

PEDIATRICS ◽

10.1542/peds.71.1.137 ◽

1983 ◽

Vol 71 (1) ◽

pp. 137-137

Author(s):

THOMAS W. SMITH

Keyword(s):

Multicenter Trial ◽

Clinical Safety ◽

Digitalis Toxicity ◽

Safety And Efficacy ◽

Fab Fragments ◽

Life Threatening ◽

September Issue

To the Editor.— Accompanying the paper of Zucker et al in the September issue of Pediatrics1 is a listing of sources from which digoxin-specific Fab fragments are stated to be available. Unfortunately, this is no longer the case. All of the individuals and institutions listed have been part of a multicenter trial of clinical safety and efficacy of purified digoxin-specific Fab fragments in the treatment of advanced, life-threatening digitalis toxicity. At the present time, however, supplies of the material are extremely limited, and several of the centers listed have exhausted their supplies of digoxin-specific Fab fragments.

Download Full-text

Digitalis Toxicity and Hypomagnesemia.

Annals of Internal Medicine ◽

10.7326/0003-4819-68-5-1161_1 ◽

1968 ◽

Vol 68 (5) ◽

pp. 1161 ◽

Cited By ~ 1

Author(s):

Robert H. Seller

Keyword(s):

Digitalis Toxicity

Download Full-text

Recognizing Digitalis Toxicity in Patients With Artificial Pacemakers

Postgraduate Medicine ◽

10.1080/00325481.1973.11713399 ◽

1973 ◽

Vol 53 (3) ◽

pp. 149-154 ◽

Cited By ~ 2

Author(s):

Edward K. Chung ◽

Donald K. Chung

Keyword(s):

Digitalis Toxicity

Download Full-text

Bidirectional Ventricular Tachycardia in a Young Female: A Case of Andersen-Tawil Syndrome

Military Medicine ◽

10.1093/milmed/usab076 ◽

2021 ◽

Author(s):

Jacob L Ransom ◽

Ka C Wong ◽

Jacqueline Kircher ◽

Courtney Usry ◽

Christopher Larson

Keyword(s):

Differential Diagnosis ◽

Ventricular Tachycardia ◽

Beta Blocker ◽

Genetic Disorder ◽

Symptom Burden ◽

Young Female ◽

Ventricular Ectopy ◽

Digitalis Toxicity ◽

Ventricular Dysrhythmia ◽

Mandibular Hypoplasia

ABSTRACT Bidirectional ventricular tachycardia (VT) is a rare ventricular dysrhythmia with a limited differential diagnosis that includes digitalis toxicity, catecholaminergic polymorphic VT, aconite poisoning, and genetic channelopathy syndromes, specifically, Andersen–Tawil syndrome (ATS). We present a case of a young female with palpitations found to have bidirectional VT on cardiac event monitor and strong family history of cardiac dysrhythmias. Her physical examination findings included minor dysmorphic features of mandibular hypoplasia, hypertelorism, and clinodactyly. The patient was clinically diagnosed with ATS and started on a beta-blocker for control of ectopy. A second Holter review demonstrated markedly decreased burden of ventricular ectopy compared to the initial monitoring. She was referred for genetic testing, which revealed a KCNJ2 mutation. Bidirectional VT is an uncommon ventricular dysrhythmia that has a limited differential diagnosis, one of which is ATS—a rare genetic disorder that results from mutations in the KCNJ2 gene. The condition is frequently associated with developmental, skeletal, and cardiac abnormalities. Although there are no strong recommendations that exist for treatment of ventricular dysrhythmias associated with this genetic disorder, we demonstrate a case of clinical improvement in a patient with ATS by using the beta-blocker metoprolol succinate. Furthermore, we propose that ATS patients may not need exercise restrictions as overall ventricular ectopy burden decreased with exercise and there was no prolongation of the QT interval. This patient will continue to follow up in our clinic to reassess symptom burden and for continued monitoring for the development of any new features.

Download Full-text